Barclays
EVH icon

Barclays’s Evolent Health EVH Stock Holding History

Barclays’s Portfolio EVH Stock Details EVH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$169K Sell
74,180
-144,961
-66% -$460K ﹤0.01% 3787
2025
Q4 		$877K Buy
219,141
+14,506
+7% +$80.6K ﹤0.01% 3531
2025
Q3 		$1.73M Sell
204,635
-920,470
-82% -$8.93M ﹤0.01% 2981
2025
Q2 		$12.7M Buy
1,125,105
+41,468
+4% +$381K ﹤0.01% 1404
2025
Q1 		$10.3M Buy
1,083,637
+168,215
+18% +$1.7M ﹤0.01% 1386
2024
Q4 		$10.3M Buy
915,422
+641,646
+234% +$11.3M ﹤0.01% 1549
2024
Q3 		$7.74M Buy
273,776
+176,445
+181% +$4.55M ﹤0.01% 1681
2024
Q2 		$1.86M Sell
97,331
-52,295
-35% -$1.34M ﹤0.01% 2201
2024
Q1 		$4.91M Sell
149,626
-107,673
-42% -$3.44M ﹤0.01% 1870
2023
Q4 		$8.5M Buy
257,299
+127,318
+98% +$3.6M ﹤0.01% 1639
2023
Q3 		$3.54M Buy
129,981
+29,672
+30% +$825K ﹤0.01% 1535
2023
Q2 		$3.04M Buy
100,309
+31,440
+46% +$1.02M ﹤0.01% 1625
2023
Q1 		$2.23M Sell
68,869
-25,273
-27% -$799K ﹤0.01% 2111
2022
Q4 		$2.64M Buy
94,142
+58,588
+165% +$1.68M ﹤0.01% 2062
2022
Q3 		$1.28M Buy
35,554
+9,623
+37% +$339K ﹤0.01% 2046
2022
Q2 		$796K Sell
25,931
-11,631
-31% -$339K ﹤0.01% 2531
2022
Q1 		$1.21M Sell
37,562
-86,667
-70% -$2.27M ﹤0.01% 2253
2021
Q4 		$3.44M Buy
124,229
+63,967
+106% +$1.84M ﹤0.01% 1983
2021
Q3 		$1.87M Buy
60,262
+35,308
+141% +$848K ﹤0.01% 2405
2021
Q2 		$527K Sell
24,954
-53,860
-68% -$1.08M ﹤0.01% 3053
2021
Q1 		$1.59M Buy
78,814
+36,642
+87% +$697K ﹤0.01% 2475
2020
Q4 		$675K Sell
42,172
-8,694
-17% -$115K ﹤0.01% 3041
2020
Q3 		$631K Sell
50,866
-9,475
-16% -$111K ﹤0.01% 3060
2020
Q2 		$430K Sell
60,341
-310,168
-84% -$2.08M ﹤0.01% 3459
2020
Q1 		$2.01M Buy
370,509
+295,933
+397% +$2.64M ﹤0.01% 2277
2019
Q4 		$674K Sell
74,576
-46,400
-38% -$377K ﹤0.01% 4032
2019
Q3 		$871K Sell
120,976
-1,474
-1% -$10.6K ﹤0.01% 3787
2019
Q2 		$972K Buy
122,450
+93,864
+328% +$1.11M ﹤0.01% 3717
2019
Q1 		$359K Sell
28,586
-32,419
-53% -$513K ﹤0.01% 4380
2018
Q4 		$1.22M Sell
61,005
-69,908
-53% -$1.62M ﹤0.01% 2914
2018
Q3 		$3.72M Buy
130,913
+23,567
+22% +$562K ﹤0.01% 2133
2018
Q2 		$2.26M Sell
107,346
-7,420
-6% -$140K ﹤0.01% 2474
2018
Q1 		$1.64M Buy
114,766
+38,151
+50% +$546K ﹤0.01% 2686
2017
Q4 		$942K Buy
76,615
+75,371
+6,059% +$1.06M ﹤0.01% 3173
2017
Q3 		$22K Sell
1,244
-25,516
-95% -$526K ﹤0.01% 5749
2017
Q2 		$679K Sell
26,760
-15,090
-36% -$363K ﹤0.01% 3224
2017
Q1 		$934K Sell
41,850
-76,882
-65% -$1.48M ﹤0.01% 2799
2016
Q4 		$1.76M Buy
118,732
+79,326
+201% +$1.56M ﹤0.01% 2238
2016
Q3 		$970K Buy
39,406
+31,906
+425% +$746K ﹤0.01% 2652
2016
Q2 		$144K Buy
+7,500
New +$103K ﹤0.01% 4150

Other funds holding EVH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RF
Rubicon Founders Nashville, Tennessee $138M AUM 61.96% 1-Year Est. Return
EC
Engaged Capital Newport Beach, California $303M AUM 2.09% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Barclays's EVH Position: Q1 2026 in Review

Barclays reduced its Evolent Health (EVH) stake by 66% in Q1 2026, selling an estimated $460K and leaving 74,180 shares worth $169K. The position accounts for ﹤0.01% of the portfolio, ranked #3787.

Barclays first reported a position in EVH in Q2 2016 and has held it in 40 quarters since. The position peaked at $12.7M in Q2 2025. 191 funds tracked by Wall St. Rank hold EVH as of Q1 2026.

  • Barclays held 74,180 shares of Evolent Health worth $169K as of Q1 2026.
  • Barclays sold 144,961 Evolent Health shares in Q1 2026, an estimated $460K.
  • Evolent Health made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3787 holding.
  • Barclays first reported a position in Evolent Health in Q2 2016 and has held it in 40 quarters since.
  • Barclays's Evolent Health position peaked at $12.7M in Q2 2025.
  • 191 funds tracked by Wall St. Rank held Evolent Health as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.